VERVE-102 for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 24 Sep 2026: Trial registered, NCT07839936
  2. 24 Sep 2026: Trial started, NCT07839936

The trials

NCT06164730: A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

State
Under way
Phase
Phase 1
People
85 planned
Started
30 Apr 2024
Primary completion
Oct 2026
Arms
Cohort 1: Single Ascending Dose Escalation, Cohort 2: Single Ascending Dose Escalation, Cohort 3: Single Ascending Dose Escalation, Cohort 4: Single Ascending Dose Escalation, Cohort 5: Single Ascending Dose Escalation, Cohort 6: Single Ascending Dose Escalation, Cohort 7: Single Ascending Dose Escalation, Cohort 8: Single Ascending Dose Escalation, Cohort 9: Single Fixed Dose, Cohort 10: Single Fixed Dose
Results
None posted
  1. 11 Dec 2023: Trial registered
  2. 30 Apr 2024: Trial started

NCT07839936: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

State
Under way
Phase
Phase 2
People
175 planned
Started
24 Sep 2026
Primary completion
Aug 2028
Arms
VERVE-102 Dose 1, VERVE-102 Dose 2, VERVE-102 Dose 3
Results
None posted
  1. 24 Sep 2026: Trial registered
  2. 24 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.